Company to submit delisting request to Nasdaq


Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced that the Combined General Meeting held today has adopted all the resolutions presented in line with the recommendations of the Board of Directors.

In particular, the shareholders approved the delisting of the Company’s shares on the Nasdaq First North market in Copenhagen and granted all powers to the Board of Directors to carry out the delisting.

The company will in the coming days formally request and ask for approval of the delisting of the company shares from trading on the Nasdaq First North from the Danish stock exchange operator.

After approval by the market operator the effective delisting of Onxeo shares from the Nasdaq First North market is expected to take place after an additional period of 10 weeks.

The company is contemplating to arrange for the automatic exchange of securities in order that Danish shareholders will be able to trade their Onxeo shares on Euronext Growth, with the same ISIN code (FR0010095596). No change will be made to the number of ordinary shares or to the rights attached to Onxeo shares and the shares will continue to be traded on Euronext Growth Paris. The share capital of the Company will therefore remain unchanged. The company will provide further details when an approval for the delisting has been obtained from Nasdaq First North.

For further information, shareholders are invited to consult the Frequently asked questions relating to the withdrawal of the Company from the Nasdaq First North market in Copenhagen, available on the Company’s website, in the General Meetings section. The result of the votes by resolution and the minutes of the meeting will be available there within the legal deadlines. Shareholders may also contact Onxeo’s investors’ relations team by email at